Screening for latent tuberculosis infection among undocumented immigrants in Swiss healthcare centres; a descriptive exploratory study. by Bodenmann, P. et al.
BioMed CentralBMC Infectious Diseases
ssOpen AcceResearch article
Screening for latent tuberculosis infection among undocumented 
immigrants in Swiss healthcare centres; a descriptive exploratory 
study
Patrick Bodenmann*1, Paul Vaucher1, Hans Wolff2, Bernard Favrat1, 
Fanny de Tribolet3, Eric Masserey4 and Jean-Pierre Zellweger1
Address: 1Department of Ambulatory Care and Community Medicine, University of Lausanne, Switzerland, 2Department of Community 
Medicine, Geneva University Hospital, Switzerland, 3Point d'Eau, Vulnerable Population Urban Healthcare Centre, Lausanne, Switzerland and 
4Department of Public Health, Canton of Vaud, Switzerland
Email: Patrick Bodenmann* - patrick.bodenmann@hospvd.ch; Paul Vaucher - paul.vaucher@hospvd.ch; Hans Wolff - hans.wolff@hcuge.ch; 
Bernard Favrat - bernard.favrat@hospvd.ch; Fanny de Tribolet - pointdeau@bluewin.ch; Eric Masserey - eric.masserey@vd.ch; Jean-
Pierre Zellweger - zellwegerjp@swissonline.ch
* Corresponding author    
Abstract
Background: Migration is one of the major causes of tuberculosis in developed countries.
Undocumented patients are usually not screened at the border and are not covered by a health
insurance increasing their risk of developing the disease unnoticed. Urban health centres could help
identify this population at risk. The objective of this study is to assess the prevalence of latent
tuberculosis infection (LTBI) and adherence to preventive treatment in a population of
undocumented immigrant patients.
Methods: All consecutive undocumented patients that visited two urban healthcare centres for
vulnerable populations in Lausanne, Switzerland for the first time were offered tuberculosis
screening with an interferon-γ assay. Preventive treatment was offered if indicated. Adherence to
treatment was evaluated monthly over a nine month period.
Results: Of the 161 participants, 131 (81.4%) agreed to screening and 125 had complete
examinations. Twenty-four of the 125 patients (19.2%; CI95% 12.7;27.2) had positive interferon-γ
assay results, two of which had active tuberculosis. Only five patients with LTBI completed full
preventive treatments. Five others initiated the treatment but did not follow through.
Conclusion: Screening for tuberculosis infection in this hard-to-reach population is feasible in
dedicated urban clinics, and the prevalence of LTBI is high in this vulnerable population. However,
the low adherence to treatment is an important public health concern, and new strategies are
needed to address this problem.
Background
Each year, more than 8 million people develop active
tuberculosis (TB) worldwide with regional variability. It is
the most common cause of death from communicable
diseases [1,2]. Movement of people between countries has
a large influence on the incidence of TB in Western-
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reported cases are due to reactivation of infections
acquired abroad but that transmission to other people in
the host country is rare [6-9]. Therefore, screening for
tuberculosis among immigrants is performed in many
developed countries with the aim of detecting and treating
the active disease [10,11] or a latent tuberculosis infection
(LTBI) [12-14]. The introduction of interferon-γ assays has
improved specificity for detecting LTBI compared with the
tuberculin skin test [15,16]. This promises a considerable
improvement in the cost-effectiveness of targeted screen-
ing programs [17-20]. However, there is no clear consen-
sus regarding the true benefits of screening and it is
difficult to assess treatment policies [21].
In practice, screening policies address immigrants that
enter into the country via an official channel (asylum
claim & working permit). In Switzerland, a screening pol-
icy exists for asylum seekers and refugees at the border,
but no system exists for undocumented immigrants from
countries with a high prevalence of tuberculosis [22,23].
The latter represent a large proportion of the foreign-born
population (estimates vary between 150,000 and 300,000
people for a total immigrant population of 7.5 million)
[24]. Targeted screening programs may be cost-effective
[25], but further studies are needed to evaluate the preva-
lence of LTBI, the acceptability of screening, and adher-
ence to treatment in this hard-to-reach vulnerable
population.
Methods
We conducted a pilot trial to investigate the acceptance,
prevalence of positive findings, and adherence to treat-
ment of undocumented immigrant patients offered LTBI
screening. We offered a free tuberculosis screening proce-
dure to all consecutive, undocumented immigrants that
were over 15 years old, had no major psychiatric disabili-
ties, and were visiting one of two low-threshold health-
care premises for the first time in Lausanne. The recruit-
ment proceeded during a six-month period in 2007 at the
Department of Ambulatory Care and Community Medi-
cine of the University Hospital and at the Point d'Eau,
Vulnerable population urban healthcare centre. Patients
were evaluated by nurse practitioners or primary care phy-
sicians trained in community medicine.
Patients were asked to answer a health questionnaire in
their preferred language that highlighted symptoms or
history that might be associated with tuberculosis (cough,
sputum, night sweating, weight loss, prior contact with
tuberculosis, prior treatment for tuberculosis, and smok-
ing). From each patient, 8 ml of blood was collected in a
Vacutainer-CPT. Within the next 24 h, an enzyme-linked
immunospot γ-interferon assay (T-Spot.TB™, Oxford
Immunotec) was performed to assess the previous tuber-
culosis infection status. This test has been shown to have
a sensitivity of 90% and a specificity of 93% to detect
latent tuberculosis [26]. If results were inconclusive, the
assay was repeated. Patients with suspect symptoms, a
prior history of tuberculosis, prior contact with tuberculo-
sis, or a positive interferon-γ test result had a chest X-ray
and a medical examination by a physician. A bacteriolog-
ical examination of sputum was performed in all patients
that had suspected symptoms or an abnormal X-ray.
Patients with active tuberculosis were treated in our
Department according to the current Swiss Guidelines
[27,28]. Patients that had a positive interferon-γ assay
with no signs of tuberculosis were offered preventive treat-
ment. Treated patients were followed for a six-month
period. We monitored the acceptance of screening, the
number of patients that returned for test results, the
number of patients that accepted treatment, and the
number of patients that finished treatment.
Sample size was calculated to assure a 0.1 margin of error
for the LTBI prevalence rate with a significant level set at
95% and an expected prevalence of 0.5 (worse case sce-
nario). We estimated that 97 patients were necessary to
sufficiently power the analysis. In anticipation of loss to
follow-up and missing data, we included 130 participants
in the study. Prevalence and acceptance rates are given
with a 95% confidence interval. Other results are given in
a descriptive form without inference, as we expected small
sample sizes.
All patients provided written informed consent for partic-
ipation, the protocol was approved by the Lausanne Uni-
versity Ethical Committee (protocol 183/06), and the
study conformed to the standards defined in the Declara-
tion of Helsinki.
Results
Between January and July 2007, 161 undocumented
immigrants that visited one of two medical centres for the
first time were asked to participate in this study. Among
these, 131 agreed to answer a questionnaire regarding
symptoms and history associated with tuberculosis and
had a blood sample drawn for an interferon-γ assay. The
questionnaire acceptance rate was 81.4% (CI95%
74.5;87.1). However, of these 131 patients, two patients
left the waiting room before seeing the practitioner, and
one refused to give a blood sample. Thus, 128 laboratory
samples were tested, and five of these were inconclusive.
Twenty-five patients (19.5%) did not return for their test
results, and three of these had an initial inconclusive lab-
oratory result. Confirmation of the inconclusive essay
revealed on positive and one negative patient. Laboratory
results were therefore available for 125 patients (Figure 1).Page 2 of 8
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Flow-chart of patient inclusion in the studyigure 1
Flow-chart of patient inclusion in the study.
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BMC Infectious Diseases 2009, 9:34 http://www.biomedcentral.com/1471-2334/9/34The demographic data are given in Table 1. The mean age
of the participants was 34.8 years, 47.2% were female, and
64% were single. Most of the patients (83.2%) entered
Switzerland without receiving the official tuberculosis
screening procedure for asylum seekers. The majority of
patients were undocumented immigrants born in Latin
America (51.2%), and many were from Sub-Saharan
Africa (19.2%). Most of the patients (76.8%) were from
countries that had a high incidence rate of active tubercu-
losis (≥ 50/100,000 per year). The mean length of time
spent in Switzerland was under two years for 52.8% of the
population. Only five out of the 24 participants that tested
positive and 15 of the 101 participants that tested negative
for TB reported previous contact with a person that had TB
Thus, the sensitivity of this question was 20.8% and the
specificity was 85.1%.
The interferon-γ assay indicated that 24 immigrants were
positive for TB (19.2%) [CI 95% 12.7–27.2]. Of these,
two had smear-positive tuberculosis (1.6%) [CI95% 0.2–
5.7], three had a history of prior treatment for tuberculo-
sis, one had a history of prior treatment for LTBI, and 18
had no active or prior tuberculosis (14.4%, CI95% 8.8–
21.8). One patient was suspected to falsely have a negative
Table 1: Population characteristics
Population characteristic Interferon-γ assay Total
Positive
n = 24
n (%)
Negative
n = 101
n (%)
n = 125
n (%)
Age
<20 0 (0) 3 (3.0) 3 (2.4)
20–39 13 (54) 78 (77) 91 (72.8)
40–59 11 (46) 18 (18)) 29 (23.2)
60 or more 0 (0) 2 (2) 2 (1.6)
Gender
Male 13 (54) 53 (52) 66 (52.8)
Level of education
Compulsory or less 11 (46) 46 (46) 55 (45.6)
Reasons for migrating
Economical 16 (64) 63 (63) 79 (63.2)
Political persecution 2 (8) 19 (19) 21 (16.8)
Religious persecution 1 (4) 2 (2) 3 (2.4)
Disease 4 (17) 2 (2) 6 (4.8)
Family grouping 4 (17) 16 (16) 20 (16)
Studies 2 (8) 8 (8) 10 (8.0)
Other 1 (4) 6 (6) 7 (5.6)
Arrived in Switzerland
Less than 2 years 12 (48) 54 (54) 66 (52.8)
2–7 years 6 (25) 38 (38) 44 (35.2)
More than 7 years 6 (24) 9 (9) 15 (12.0)
Tobacco
Smoker 9 (37) 39 (39) 48 (38.4)
Close contact with TBC
Reported 5 (21) 15 (15) 20 (16.0)
Not reported 19 (79) 86 (85) 20 (84.0)
Proximity of at least one hour with someone during previous 3 months
Disco or dancing 8 (33) 43 (43) 51 (40.8)
Religious meetings 10 (42) 41 (41) 51 (40.8)
Interior sports 1 (4) 22 (22) 23 (18.4)
Restaurants or pubs 4 (17) 16 (16) 20 (16)
Welfare hostel 1 (4) 5 (4) 6 (4.8)
Other 1 (4) 8 (8) 9 (7.2)Page 4 of 8
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confirmed active tuberculosis two years previously.
The two patients with active tuberculosis were isolated
and treated according to the current Swiss Guidelines
[27]. Both were adherent to treatment and were cured.
Among the 14 immigrants with no prior history of TB and
a positive interferon-γ assay result, four had counter-indi-
cations for preventive treatment (high age, liver disease),
four did not show up for further examinations, and 10
accepted preventive treatment for LTBI. Of the 10 that
accepted preventative treatment, only five followed the
treatment until the scheduled completion. Therefore, full
treatment was sustained by 5/18 patients with LTBI (Fig-
ure 2).
Discussion
In our study, 19.2% (24/125) of the undocumented
immigrant patients had positive interferon-γ assay results
and 14.4% (18/125) had LTBI that was previously unde-
tected. Carvalho et al [25] found similar results (15%; 15/
100) for undocumented immigrant patients attending an
Italian health care service. Although the sample sizes were
small in both these studies, the observed prevalence of
positive interferon-γ results appeared to be substantial
compared to other population groups, including: German
subjects that had been in close contact with an index case
(10%) [29], healthcare workers in Denmark (1.4%)[30]
or Japan (9.9%)[31], American Navy recruits (0.6%)[32],
and the general Japanese population (7.1%)[33]. Prior
exposure to an index case with pulmonary TB in the coun-
try of origin appeared to be the primary cause of LTBI in
low-incidence rate countries [3]. Furthermore, the risk of
reactivating a LTBI into active tuberculosis seemed to
mainly be related to the initial exposure in high incidence
countries of origin and not to other risk behaviours or
environmental conditions in the host country [7,34].
More than 3/4 of undocumented immigrants consulting
healthcare centres in Western Switzerland are from coun-
tries with incidence rates of tuberculosis above 50 cases/
100,000 people per year. This is most likely the major rea-
son for the high prevalence of LTBI in this population.
Targeted tuberculosis screening seems to be more cost-
effective for preventing outbreaks than systematic screen-
ing [17,21]. Clinical trials have shown that preventive
treatment reduced infection rates by more than half when
strict adherence was achieved [14,35]. Most cost-effective-
ness studies [18-20,36,37] are based on estimates that do
not take into consideration the number of positive inter-
feron-γ assays that are due to past infections where treat-
ment was interrupted. Nevertheless, our study showed a
potential benefit of screening and offering preventive
therapy for this specific vulnerable population. Preventing
the emergence of new index cases in this hard-to-reach
population that often lives in close quarters could sub-
stantially reduce expenses related to controlling an out-
break [38]. The high prevalence of LTBI suggests that
screening with an interferon-γ assay could be cost-effective
under conditions that promoted adherence to the end of
therapy for most patients [36]. However, the risk of devel-
oping tuberculosis is much higher for individuals with
positive intereron-γ results than those with a positive
tuberculosis skin test [39].
The acceptance rate for screening was high (81.4%). Using
nurse practitioners and trained primary physicians in
secure environments could help build the trust of this
hard-to-reach population. Maintaining confidentiality
could be essential to assure trust [40].
On the other hand, there are obstacles in ensuring that
patients follow their treatment to the end. Only five
patients out of eighteen with LTBI completed the preven-
tive therapy in our study. Ailinger et al [41] observed an
adherence prevalence of 72% for Latino patients that were
undocumented immigrants in Washington DC. A prior
study from our institution observed that the rate of adher-
ence was 76% in a group composed mainly of foreign
workers and refugees [42]. Therefore, adherence to treat-
ment may depend on the setting and the confidence the
patients have in the system (fear of denunciation and
rejection). Supervising [43] or monitoring [44] drug
administration, offering free access to care [45], using
models of explanation based on the patient's representa-
tion of his own health [46], and relying on trained nurse
practitioners for screening [47,48] could improve compli-
ance. Furthermore, compared to tuberculosis skin tests,
the introduction of interferon-γ assays has largely
improved the specificity of LTBI detection; thus, the
number of patients that would receive preventive treat-
ment without needing it can be reduced. This knowledge
might raise the motivation of healthcare workers in their
efforts to follow patients and help them adhere to the pro-
posed treatment.
Our study has several weaknesses. The small size of the
population sample led to a lack of precision in the results.
The absence of a non-migrant control group made it diffi-
cult to compare the prevalence of LTBI in migrants with
that of the local population; however, we considered it
safe to assume that the local population living in Switzer-
land had a much lower prevalence of LTBI than the study
population. The setting of our study could limit the gen-
eralisability of our results to rural migrants attending a
healthcare centre. Patients who do not attend a healthcare
centre could be younger and less deprived than those
included in the study. Our population could be more at
risk to have been in contact with tuberculosis. Our results
are therefore limited to quantifying the prevalence ofPage 5 of 8
(page number not for citation purposes)
BMC Infectious Diseases 2009, 9:34 http://www.biomedcentral.com/1471-2334/9/34latent tuberculosis in a setting in which it is possible to
consider targeted screening and prevention programs to
take place. Finally, interferon-γ positivity may not equate
perfectly with latent TB infection. As such additionally
data using another interferon-γ or the tuberculosis skin
test would have been helpful.
Conclusion
Our study shows the benefit of using highly sensitive
assays for detecting LTBI on targeted populations at risk
that easily accept screening in appropriate health settings
by trained nurse practitioners and primary care physi-
cians. Nevertheless, methods for improving adherence to
Adherence to therapy from testing to the end of prophylactic therapiesFigur  2
Adherence to therapy from testing to the end of prophylactic therapies. * Total number of participants with LTBI 
was expected to be 18. We assumed that the four patients that did not show up for further examination did not have active 
TB.
Positive T-Spot
n=24 (19.2%)
Complementary 
exams
n=16 
Started therapy
n=10 
TB
n=2 
(1.6%)
LTBI
n=14 
(11.2%)*
Hospitalised
n=2 
Ended therapy
n=5 
Did not have X-ray
• Already treated for TB/LTBI 4
• Did not show-up for exam 4
Surveillance
n=4 
Counter-indicated
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BMC Infectious Diseases 2009, 9:34 http://www.biomedcentral.com/1471-2334/9/34treatment are lacking. Our results demonstrate the high
prevalence of LTBI in migrants and emphasize the need
for developed countries to invest in programs that reduce
the transmission of tuberculosis worldwide; in particular,
the focus should be on undocumented migrants that fre-
quently come from countries with high incidence rates of
tuberculosis.
Abbreviations
LTBI: latent tuberculosis infection; TB: active tuberculosis;
CI: confidence interval; HIV: human immunodeficiency
virus.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
PB has made substantive contribution to conception,
acquisition of data, design and interpretation of data. PV
has contributed to conception, design, analysis and inter-
pretation of data. PB and PV have drafted the manuscript.
HW, BF and EM have contributed to the interpretation of
data and critically revised the manuscript. FdT has con-
tributed to acquisition of data and revising the manu-
script. JPZ has made contribution to conception and
design, interpretation of data and has revised the manu-
script with important intellectual content. All authors
have given their approval for this version to be published.
Acknowledgements
We thank those who have financed our study: The State Department of 
Health of Vaud, the Migration Friendly Hospital Association, and the Swiss 
Lung League.
References
1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC: Consensus
statement. Global burden of tuberculosis: estimated inci-
dence, prevalence, and mortality by country. WHO Global
Surveillance and Monitoring Project.  Jama 1999,
282(7):677-686.
2. WHO: Global tuberculosis control: surveillance, planning,
financing. WHO report 2007.  2007 [http://www.who.int/tb/pub
lications/global_report/2007/pdf/full.pdf]. Geneva: WHO
3. MacPherson DW, Gushulak BD: Balancing prevention and
screening among international migrants with tuberculosis:
population mobility as the major epidemiological influence
in low-incidence nations.  Public health 2006, 120(8):712-723.
4. Walls T, Shingadia D: The epidemiology of tuberculosis in
Europe.  Archives of disease in childhood 2007, 92(8):726-729.
5. Laifer G, Widmer AF, Simcock M, Bassetti S, Trampuz A, Frei R,
Tamm M, Battegay M, Fluckiger U: TB in a low-incidence country:
differences between new immigrants, foreign-born residents
and native residents.  The American journal of medicine 2007,
120(4):350-356.
6. Dahle UR, Eldholm V, Winje BA, Mannsaker T, Heldal E: Impact of
immigration on the molecular epidemiology of Mycobacte-
rium tuberculosis in a low-incidence country.  American journal
of respiratory and critical care medicine 2007, 176(9):930-935.
7. Lillebaek T, Andersen AB, Bauer J, Dirksen A, Glismann S, de Haas P,
Kok-Jensen A: Risk of Mycobacterium tuberculosis transmis-
sion in a low-incidence country due to immigration from
high-incidence areas.  Journal of clinical microbiology 2001,
39(3):855-861.
8. Dahle UR, Sandven P, Heldal E, Caugant DA: Continued low rates
of transmission of Mycobacterium tuberculosis in Norway.
Journal of clinical microbiology 2003, 41(7):2968-2973.
9. Maguire H, Dale JW, McHugh TD, Butcher PD, Gillespie SH, Costet-
sos A, Al-Ghusein H, Holland R, Dickens A, Marston L, et al.: Molec-
ular epidemiology of tuberculosis in London 1995–7 showing
low rate of active transmission.  Thorax 2002, 57(7):617-622.
10. Welshman J, Bashford A: Tuberculosis, migration, and medical
examination: lessons from history.  Journal of epidemiology and
community health 2006, 60(4):282-284.
11. Rieder HL, Zellweger JP, Raviglione MC, Keizer ST, Migliori GB:
Tuberculosis control in Europe and international migration.
Eur Respir J 1994, 7(8):1545-1553.
12. Lalvani A: Spotting latent infection: the path to better tuber-
culosis control.  Thorax 2003, 58(11):916-918.
13. Blumberg HM, Leonard MK Jr, Jasmer RM: Update on the treat-
ment of tuberculosis and latent tuberculosis infection.  Jama
2005, 293(22):2776-2784.
14. Chee CB, Teleman MD, Boudville IC, Do SE, Wang YT: Treatment
of latent TB infection for close contacts as a complementary
TB control strategy in Singapore.  Int J Tuberc Lung Dis 2004,
8(2):226-231.
15. Menzies D, Pai M, Comstock G: Meta-analysis: new tests for the
diagnosis of latent tuberculosis infection: areas of uncer-
tainty and recommendations for research.  Annals of internal
medicine 2007, 146(5):340-354.
16. Ewer K, Deeks J, Alvarez L, Bryant G, Waller S, Andersen P, Monk P,
Lalvani A: Comparison of T-cell-based assay with tuberculin
skin test for diagnosis of Mycobacterium tuberculosis infec-
tion in a school tuberculosis outbreak.  Lancet 2003,
361(9364):1168-1173.
17. Dasgupta K, Menzies D: Cost-effectiveness of tuberculosis con-
trol strategies among immigrants and refugees.  Eur Respir J
2005, 25(6):1107-1116.
18. Porco TC, Lewis B, Marseille E, Grinsdale J, Flood JM, Royce SE:
Cost-effectiveness of tuberculosis evaluation and treatment
of newly-arrived immigrants.  BMC public health 2006, 6:157.
19. Oxlade O, Schwartzman K, Menzies D: Interferon-gamma
release assays and TB screening in high-income countries: a
cost-effectiveness analysis.  Int J Tuberc Lung Dis 2007,
11(1):16-26.
20. Diel R, Nienhaus A, Loddenkemper R: Cost-effectiveness of inter-
feron-gamma release assay screening for latent tuberculosis
infection treatment in Germany.  Chest 2007,
131(5):1424-1434.
21. Coker R: Compulsory screening of immigrants for tuberculo-
sis and HIV.  BMJ (Clinical research ed) 2004, 328(7435):298-300.
22. Zellweger JP, Helbling P: Tuberculosis in Switzerland: from san-
atorium guests to immigrants.  Monaldi Arch Chest Dis 1997,
52(3):234-236.
23. Bodenmann P, Depallens VM, Schoch M, Puelma M, Pécoud A, Gehri
M: Etre malade et "sans-papiers" à Lausanne: Quo vadis?
Médecine et Hygiène 2003, 545:2023-2028.
24. Longschamps C, Aebersold E, Rousselot B, Ratelband-Pally S: "Sans-
papiers" in der Schweiz Arbeitsmarkt, nicht Asylpolitik
istentscheidend.  2005.
25. Carvalho AC, Pezzoli MC, El-Hamad I, Arce P, Bigoni S, Scarcella C,
Indelicato AM, Scolari C, Carosi G, Matteelli A: QuantiFERON-TB
Gold test in the identification of latent tuberculosis infection
in immigrants.  The Journal of infection 2007, 55(2):164-168.
26. Pai M, Zwerling A, Menzies D: T-Cell-Based Assays for the Diag-
nosis of Latent Tuberculosis Infection: An Update.  Ann Intern
Med 2008, 149(3):177-184.
27. Ligue Pulmonaire Suisse: Manuel de la Tuberculose.  2007 [http:/
/www.tbinfo.ch/uploads/media/
Handbuch_Tuberkulose_f_140507.pdf].
28. Zelwegger J-P: Treatment of tuberculosis.  Expert Rev Respir Med
2007, 1(1):85-97.
29. Diel R, Nienhaus A, Lange C, Schaberg T: Cost-optimisation of
screening for latent tuberculosis in close contacts.  Eur Respir
J 2006, 28(1):35-44.
30. Soborg B, Andersen AB, Larsen HK, Weldingh K, Andersen P, Kofoed
K, Ravn P: Detecting a low prevalence of latent tuberculosis
among health care workers in Denmark detected by M.
tuberculosis specific IFN-gamma whole-blood test.  Scandina-
vian journal of infectious diseases 2007, 39(6–7):554-559.Page 7 of 8
(page number not for citation purposes)
BMC Infectious Diseases 2009, 9:34 http://www.biomedcentral.com/1471-2334/9/34Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
31. Harada N, Nakajima Y, Higuchi K, Sekiya Y, Rothel J, Mori T: Screen-
ing for tuberculosis infection using whole-blood interferon-
gamma and Mantoux testing among Japanese healthcare
workers.  Infect Control Hosp Epidemiol 2006, 27(5):442-448.
32. Mazurek GH, Zajdowicz MJ, Hankinson AL, Costigan DJ, Toney SR,
Rothel JS, Daniels LJ, Pascual FB, Shang N, Keep LW, et al.: Detection
of Mycobacterium tuberculosis infection in United States
Navy recruits using the tuberculin skin test or whole-blood
interferon-gamma release assays.  Clin Infect Dis 2007,
45(7):826-836.
33. Mori T, Harada N, Higuchi K, Sekiya Y, Uchimura K, Shimao T: Wan-
ing of the specific interferon-gamma response after years of
tuberculosis infection.  Int J Tuberc Lung Dis 2007,
11(9):1021-1025.
34. Patel S, Parsyan AE, Gunn J, Barry MA, Reed C, Sharnprapai S, Hors-
burgh CR Jr: Risk of progression to active tuberculosis among
foreign-born persons with latent tuberculosis.  Chest 2007,
131(6):1811-1816.
35. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM: Isoniazid for pre-
venting tuberculosis in non-HIV infected persons.  Cochrane
database of systematic reviews (Online) 2000:CD001363.
36. Diel R, Wrighton-Smith P, Zellweger JP: Cost-effectiveness of
interferon-{gamma} release assay testing for the treatment
of latent tuberculosis.  Eur Respir J 2007, 30(2):321-332.
37. Wrighton-Smith P, Zellweger JP: Direct costs of three models for
the screening of latent tuberculosis infection.  Eur Respir J 2006,
28(1):45-50.
38. Reynard C, Zuberbuehler D, Zellweger J: Tuberculosis among
illegal immigrants in Lausanne, Switzerland. Conférence
mondiale sur la tuberculose et les maladies respiratoires.
Paris.  2001.
39. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus
A: Predictive Value of a Whole-blood IFN-{gamm} Assay for
the Development of Active TB Disease.  American journal of res-
piratory and critical care medicine 2008, 177(10):1164-70.
40. Bayoumi AM, Hwang SW: Methodological, practical, and ethical
challenges to inner-city health research.  J Urban Health 2002,
79(4 Suppl 1):S35-42.
41. Ailinger RL, Moore JB, Nguyen N, Lasus H: Adherence to latent
tuberculosis infection therapy among latino immigrants.
Public health nursing (Boston, Mass) 2006, 23(4):307-313.
42. Racine-Perreaud E, Zellweger JP: Chimiothérapie antitubercu-
leuse préventive chez 250 patients du Dispensaire antituber-
culeux de Lausanne.  Schweizerische medizinische Wochenschrift
1994, 124(17):705-711.
43. Matteelli A, Casalini C, Raviglione MC, El-Hamad I, Scolari C, Bom-
bana E, Bugiani M, Caputo M, Scarcella C, Carosi G: Supervised pre-
ventive therapy for latent tuberculosis infection in illegal
immigrants in Italy.  Am J Respir Crit Care Med 2000,
162(5):1653-1655.
44. Moulding TS: Viewpoint: adapting to new international tuber-
culosis treatment standards with medication monitors and
DOT given selectively.  Trop Med Int Health 2007,
12(11):1302-1308.
45. Marjanovic Z, Tuppin P, Herrmann JL, Bayol G, Toledano C, Farge D:
Tuberculosis in patients with and without primary health
coverage.  Eur J Intern Med 2002, 13(3):180-184.
46. McEwen MM: Mexican immigrants' explanatory model of
latent tuberculosis infection.  J Transcult Nurs 2005,
16(4):347-355.
47. Horrocks S, Anderson E, Salisbury C: Systematic review of
whether nurse practitioners working in primary care can
provide equivalent care to doctors.  BMJ (Clinical research ed)
2002, 324(7341):819-823.
48. Koehn PH, Sainola-Rodriguez K: Clinician/patient connections in
ethnoculturally nonconcordant encounters with political-
asylum seekers: a comparison of physicians and nurses.  J
Transcult Nurs 2005, 16(4):298-311.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/9/34/prepubPage 8 of 8
(page number not for citation purposes)
